These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 19777160)
1. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. Roy Choudhury S; Karmakar S; Banik NL; Ray SK Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160 [TBL] [Abstract][Full Text] [Related]
2. Bcl-2 inhibitor HA14-1 and genistein together adeptly down regulated survival factors and activated cysteine proteases for apoptosis in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells. Mohan N; Karmakar S; Choudhury SR; Banik NL; Ray SK Brain Res; 2009 Aug; 1283():155-66. PubMed ID: 19505441 [TBL] [Abstract][Full Text] [Related]
3. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Rosato RR; Almenara JA; Coe S; Grant S Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059 [TBL] [Abstract][Full Text] [Related]
4. Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells. Das A; Banik NL; Ray SK Int J Oncol; 2009 Mar; 34(3):757-65. PubMed ID: 19212680 [TBL] [Abstract][Full Text] [Related]
5. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558 [TBL] [Abstract][Full Text] [Related]
6. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Liu Q; Mier JW; Panka DJ Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745 [TBL] [Abstract][Full Text] [Related]
7. Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells. Hossain MM; Banik NL; Ray SK Exp Cell Res; 2012 Aug; 318(13):1597-610. PubMed ID: 22507272 [TBL] [Abstract][Full Text] [Related]
8. Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways. Karmakar S; Davis KA; Choudhury SR; Deeconda A; Banik NL; Ray SK Biochem Biophys Res Commun; 2009 Oct; 388(4):705-10. PubMed ID: 19695221 [TBL] [Abstract][Full Text] [Related]
9. Synergistic efficacy of a novel combination therapy controls growth of Bcl-x(L) bountiful neuroblastoma cells by increasing differentiation and apoptosis. Mohan N; Banik NL; Ray SK Cancer Biol Ther; 2011 Nov; 12(9):846-54. PubMed ID: 21878749 [TBL] [Abstract][Full Text] [Related]
10. The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. Brüning A; Rahmeh M; Gingelmaier A; Friese K Mol Cancer; 2010 Jan; 9():19. PubMed ID: 20105315 [TBL] [Abstract][Full Text] [Related]
11. N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53. Janardhanan R; Banik NL; Ray SK Biochem Pharmacol; 2009 Nov; 78(9):1105-14. PubMed ID: 19540207 [TBL] [Abstract][Full Text] [Related]
13. Genistein induces receptor and mitochondrial pathways and increases apoptosis during BCL-2 knockdown in human malignant neuroblastoma SK-N-DZ cells. George J; Banik NL; Ray SK J Neurosci Res; 2010 Mar; 88(4):877-86. PubMed ID: 19813266 [TBL] [Abstract][Full Text] [Related]
14. Synergistic activity of letrozole and sorafenib on breast cancer cells. Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642 [TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Huang S; Sinicrope FA Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401 [TBL] [Abstract][Full Text] [Related]
16. SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells. Mohan N; Karmakar S; Banik NL; Ray SK Neurochem Res; 2011 Aug; 36(8):1383-96. PubMed ID: 21472456 [TBL] [Abstract][Full Text] [Related]
17. N-Myc knockdown and apigenin treatment controlled growth of malignant neuroblastoma cells having N-Myc amplification. Hossain MM; Banik NL; Ray SK Gene; 2013 Oct; 529(1):27-36. PubMed ID: 23941992 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Oh SJ; Erb HH; Hobisch A; Santer FR; Culig Z Endocr Relat Cancer; 2012 Jun; 19(3):305-19. PubMed ID: 22383427 [TBL] [Abstract][Full Text] [Related]
19. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197 [TBL] [Abstract][Full Text] [Related]
20. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Chai H; Luo AZ; Weerasinghe P; Brown RE Int J Clin Exp Pathol; 2010 Apr; 3(4):408-15. PubMed ID: 20490331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]